Eris Lifesciences Ltd has released an investor presentation detailing Q1 FY26 financial highlights, with an 11% growth in Domestic Branded Formulations and a 41% increase in PAT/EPS. The presentation emphasizes improved operating margins and the commencement of insulin vial manufacturing.